Clinical trial
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00205660 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00205660 |
|---|---|
| Title | Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole |
| Official title | Changes in Adiposity and Metabolic Measures During Medication Switches to Aripiprazole From Other Atypical Antipsychotics |
| Acronym | BMS |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Type 2 Diabetes Mellitus |
| Intervention type | Other |
| Interventions | Stayers, Switchers |
| Enrollment | 51 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 15, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: